Oculis wins FDA IND clearance for Privosegtor in acute MS relapses
AI Summary- Oculis received FDA clearance to develop Privosegtor for acute multiple sclerosis relapses.
- The proposed regimen uses 3mg/kg daily for five days, matching PIONEER-1.
- Oculis plans an R&D Day on December 8, 2026.